Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SIGMAROC PLC Board/Management Information 2019

Feb 7, 2019

7917_rns_2019-02-07_61930cf3-f4d3-4ab7-a51b-5f00185a4335.html

Board/Management Information

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4175P

SigmaRoc PLC

07 February 2019

SigmaRoc plc / EPIC: SRC / Market: AIM / Sector: Construction & Materials

7 February 2019

SigmaRoc plc

('SigmaRoc', the 'Company' or the 'Group')

Appointment of Broker

SigmaRoc plc, the AIM quoted buy-and-build construction materials group, is pleased to announce the appointment, with immediate effect, of Liberum Capital Limited as its joint broker, alongside its existing broker, Berenberg.

Further information on the Group can be found at SigmaRoc's website: www.sigmaroc.com.

Enquiries:

SigmaRoc Tel: +44(0)207 129 7828
Max Vermorken, CEO
Strand Hanson (Nominated and Financial adviser) Tel: +44(0)207 409 3494
James Spinney / James Dance / Jack Botros
Liberum Capital (Joint Broker) Tel: +44(0)203 100 2000
Neil Patel / Jamie Richards / Jonathan Wilkes-Green / William Hall
Berenberg (Joint Broker) Tel: +44(0)203 207 7800
Ben Wright / Mark Whitmore / Laure Fine
Investor Relations Tel: +44(0)207 129 7828
Ian Osburn / Ben Feder [email protected]

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

APPLLFSSFSIDIIA